Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.
New Lyme disease study in the Netherlands At the start of the “Tick Awareness Week”, the Dutch National Institute for Public Health and the Environment (RIVM) and Wageningen UR are commencing a large-scale study on the long-term effects of
Innovation required in risk assessment of nanoparticles The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.
RIVM researchers win best paper award of the journal Risk Analysis RIVM researchers Arie Havelaar and Arno Swart received the prestigious Best Paper Award 2014 of the Society for Risk Analysis.
RIVM participates in large EU project to head up global fight against infectious diseases COMPARE, a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology.
Possibly more cases of gastroenteritis caused by antacids In recent years the Netherlands has witnessed an increase in the number of cases of gastroenteritis caused by the Campylobacter bacterium.
RIVM involvement in UN/EU missions RIVM-experts from the Environmental Assessment Unit (EAU) have undertaken two missions involving an emergency situation in the Solomon Islands and an environmental assessment in Georgia.
RIVM film about nanomaterials RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.
RIVM provides support during the Nuclear Security Summit RIVM is in a state of readiness to assist and support the fire brigade, the Dutch National Police Service (KLPD) and the Regional Emergency Health Organisation (GHOR) in the event of any disasters
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.